Accueil   Agenda - News   Toutes les news ORPHELIA Pharma and K.S. KIM (SK-Pharma) sign a license agreement for the distribution of Kigabeq® in the territory of the Russian federation

ORPHELIA Pharma and K.S. KIM (SK-Pharma) sign a license agreement for the distribution of Kigabeq® in the territory of the Russian federation

 

 

Paris and Tel Aviv – November 16th 2021 – ORPHELIA Pharma and K.S. KIM INTERNATIONAL (SKPHARMA) LTD announce today the execution of an exclusive distribution and marketing agreement for Kigabeq® (vigabatrin) in the territory of the Russian Federation.

 

Kigabeq®, the first pediatric form of vigabatrin developed by ORPHELIA Pharma, is notably indicated in the treatment of infantile spasms (West syndrome). Kigabeq® is approved in the European Union, where this medicine, intended exclusively for children, benefits from a centralized marketing authorization (Pediatric Use Marketing authorization, PUMA).

 

Lire le communiqué de presse